Login to Your Account



Clinic Roundup


Tuesday, August 9, 2011
Chelsea Therapeutics Ltd., of Charlotte, N.C., reached its target enrollment of 120 patients in a Phase II trial of its fibromyalgia candidate, droxidopa.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription